Michael Morrison
Senior Researcher in Social Science
Biography
Michael has an MA (by Research and Thesis) and PhD from the interdisciplinary Institute for Science and Society (ISS) at the University of Nottingham. He also holds a BSc in Biology from the University of St. Andrews (2000). Michael has recently acted as Principal Investigator on the ESRC-funded project 'Biomodifying technologies and experimental space’, (2017-2020) and its 'sister' project BioGov: Governing biomodification in the life sciences' with professor Kaye. Both projects involved collaboration between researchers from the Universities of Oxford, Sussex and York to examine three '‘gateway technologies’ with wide-ranging applications in medicine and the life sciences; gene editing, induced pluripotent stem cells, and 3D printing of living material. Each of these technologies enables researchers to modify living biological tissue in novel and increasingly patient-orientated and customized ways, which challenge the suitability of traditional manufacturing, governance and reimbursement pathways designed for small molecule pharmaceuticals or medical devices.
Michael has previously worked on a number of biomedical research projects including; STEMBANCC , Dynamic Consent, BioModifying Technologies, BioGOV: Governing biomodification in the life sciences and the EUCelLEX assessing how current European legislation is applied in different countries in the light of scientific, legal and institutional developments. He has also been a researcher on the European Framework Programme 7 'Regenerative Medicine in Europe' (REMEDiE) project at the University of York. More details on his research, review activity and publications can be found via ResearchGate and his ORCID profile.
Publications
Kantor J and others, ‘Oxford Vaccine Hesitancy Scale (OVHS): a UK-based and US-based online mixed-methods psychometric development and validation study of an instrument to assess vaccine hesitancy.’ (2024) 14(10) BMJ Open e084669
Kantor J and others, ‘The Oxford Needle Experience (ONE) scale: a UK-based and US-based online mixed-methods psychometric development and validation study of an instrument to assess needle fear, attitudes and expectations in the general public’ (2023) 13(12) BMJ Open
Asquer A and Morrison M, ‘Editorial: Regulation and governance of gene editing technologies (CRISPR, etc.)’ (2022) 4 Frontiers in Political Science
Bicudo E and others, ‘Patent power in biomedical innovation: technology governance in biomodifying technologies’ (2022) 25(2) Journal of World Intellectual Property 473
Morrison M and Bartlett A, ‘Making translational value: identifying ‘good targets’ for clinical research on gene editing and induced pluripotent stem cell technologies’ (2022) 2 SSM - Qualitative Research in Health
MOURBY M and others, ‘Biomodifying the ‘Natural’: from Adaptive Regulation to Adaptive Societal Governance’ [2022] Journal of Law and the Biosciences
Bin Abdul Aziz M, Morrison M and Kaye J, ‘Creative regulatory practices to develop stem-cell technology: the way forward for Malaysia’ (2021) 17(2) Regenerative Medicine 91
Umemura M and Morrison M, ‘Comparative lessons in regenerative medicine readiness: learning from the UK and Japanese experience’ (2021) 16(3) Regenerative Medicine 269
Morrison M and others, ‘Spatiotemporal readiness is key to preparing regenerative medicine for the clinic’ (2021) 16(3) Regenerative Medicine 229
Morrison M and others, ‘Governance of research consortia: challenges of implementing Responsible Research and Innovation within Europe’ (2020) 16(1) Life Sciences, Society and Policy
Morrison M, ‘Making bio-objects mobile: behind the scenes of a translational stem cell banking consortium’ [2020] BioSocieties
Martin P and others, ‘Genome editing: the dynamics of continuity, convergence, and change in the engineering of life’ [2020] New Genetics and Society 1
MOURBY M and MORRISON M, ‘Gene Therapy Regulation: Could In-Body Editing Fall Through The Net?’ [2020] European Journal of Human Genetics
Morrison M and de Saille S, ‘CRISPR in context: towards a socially responsible debate on embryo editing’ (2019) 5(1) Palgrave Communications
Feeney O and others, ‘Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies’ (2018) 18(12) The American Journal of Bioethics 36
Morrison M, ‘Valuing height: diagnosis, valuation and the case of idiopathic short stature.’ [2018] Sociology of Health & Illness
MORRISON M, ‘Making Cells Worthwhile: Calculations of Value in a European Consortium for Induced Pluripotent stem cell banking’ [2018] Science As Culture
Morrison M, Minari J and Brothers K, ‘Tensions in ethics and policy created by National Precision medicine Programs’ [2018] Human Genomics
Kaye J and others, ‘Including all voices in international data-sharing governance.’ (2018) 12(1) Human Genomics 13
Bin Abdul Aziz M, Morrison M and Kaye J, ‘Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives’ [2017] New Genetics and Society 1
Nicol D and others, ‘Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.’ (2017) 9(1) Genome Medicine 85
Morrison M and others, ‘The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks.’ (2017) 12(6) Regenerative Medicine 693
Morrison M, ‘"A good collaboration is based on unique contributions from each side": assessing the dynamics of collaboration in stem cell science.’ (2017) 13(1) Life Sci Soc Policy 7
Morrison M, ‘Infrastructural expectations: exploring the promise of international large-scale induced pluripotent stem cell banks’ (2017) 36(1) New Genetics and Society 66
Morrison M, ‘Overdiagnosis, medicalisation and social justice: commentary on Carter et al (2016) ‘A definition and ethical evaluation of overdiagnosis’’ [2016] Journal of Medical Ethics medethics-2016-103717
Bezuidenhout L and Morrison M, ‘Between Scylla and Charybdis: Reconciling competing data management demands in the life sciences.’ (2016) 17(1) BMC Medical Ethics
Morrison M, Moraia L and Steele J, ‘Traceability in stem cell research: from participant sample to induced pluripotent stem cell and back.’ (2016) 11(1) Regenerative Medicine 73
Morrison M and others, ‘StemBANCC: Governing access to material and data in a large stem cell research consortium.’ (2015) 11(5) Stem Cell Reviews 681
Teare H and others, ‘Towards ’Engagement 2.0’: Insights from a study of dynamic consent with biobank participants’ (2015) 1 Digital Health 1
Morrison M, ‘STS and enhancement technologies: A programme for future research’ (2015) 28(2) Science and Technology Studies 3
Kaye J and others, ‘Dynamic consent: a patient interface for twenty-first century research networks.’ (2015) 23(2) European Journal of Human Genetics : EJHG 141
Melham K and others, ‘The evolution of withdrawal: negotiating research relationships in biobanking.’ (2014) 10 Life Sciences, Society and Policy 16
Morrison M, ‘[Book Review] Me medicine vs. we medicine: reclaiming biotechnology for the common good’ [2013] New Genetics and Society
Morrison M, ‘Promissory futures and possible pasts: The dynamics of contemporary expectations in regenerative medicine’ (2012) 7(1) BioSocieties 3
Morrison M and Cornips L, ‘Exploring the Role of Dedicated Online Biotechnology News Providers in the Innovation Economy’ (2012) 37(3) Science, Technology, & Human Values 262
Bahadur G and Morrison M, ‘Patenting human pluripotent cells: balancing commercial, academic and ethical interests.’ (2010) 25(1) Human Reproduction (Oxford, England) 14
MORRISON M, ‘The role of patenting in the valuation of biomedical innovation’ Technoscienza
Morrison M, ‘Human Tissue’ 1197
MORRISON M, ‘(Genome) Editing Future Societies’ in P Martin and others (eds.), Being Human During Covid-19 (Bristol University Press 2022)
Morrison M and Kelly S, ‘Personalised medicine’, Routledge International Handbook of Critical Issues in Health and Illness (Routledge 2021)
MORRISON M and others, ‘Implications of secondary findings for clinical contexts’ in M Langanke, P Erdmann and K Brothers (eds.), Secondary Findings in Genomic Research (Academic Press 2020)
Morrison M and others, ‘Chapter 8 Implications of secondary findings for clinical contexts’, Secondary Findings in Genomic Research (Elsevier 2020)
Morrison M, Hogarth S and Kewell B, ‘Biocapital and Innovation Paths: The Exploitation of Regenerative Medicine’ in A Webster (ed.), The Global Dynamics of Regenerative Medicine: A Social Science Critique (Palgrave Macmillan 2013)
Gardner J and MORRISON M, ‘Australia’s medical innovation approach: is it suitable for regenerative medicine?’ (Open Access Government, 3 December 2021)
MORRISON M and Umemura M, ‘Japan: A case study of national ‘readiness’ for regenerative medicine.’ (Open Access Government, 7 September 2021)
Morrison M, ‘Policy briefing: Trends in customization and personalization of advanced therapies’ (RegMedNet.com, 1 February 2021)
Morrison M, ‘Policy briefing: Accelerating innovation: speed and timing in translational research’ (RegMedNet.com, 1 September 2020)
Morrison M, ‘Policy briefing: Making ’good targets’ for translational research’ (RegMedNet.com, 1 July 2020)
MORRISON M, ‘The promises and challenges of biomodifying technologies for the UK’ (Opern Access Government, 2 July 2019)
MORRISON M and others, ‘Reshaping the landscape of science and medicine’ (Science Impact Ltd, 22 February 2019)
Takashima K, Morrison M and Minari J, ‘Reflection on the enactment and impact of safety laws for regenerative medicine in Japan’ (2021) 16(6) Stem Cell Reports 1425 (review)
Morrison M, ‘Growth hormone, enhancement and the pharmaceuticalisation of short stature.’ (2015) 131 Social Science & Medicine (1982) 305 (review)
Bahadur G, Morrison M and Machin L, ‘Beyond the ’embryo question’: human embryonic stem cell ethics in the context of biomaterial donation in the UK.’ (2010) 21(7) Reproductive Biomedicine Online 868 (review)
Morrison M, ‘The matrix of stem cell research: an approach to rethinking science in society’ (2022) Taylor & Francis 358
MORRISON M, ‘Report from the joint MHRA Patient Forum on Biomodifying technologies.’ (2021)
MORRISON M, ‘Biomodifying technologies Policy Briefing 3 “Trends in customisation and personalisation of advanced therapies”.’ (2021) RegMedNet
Morrison M, ‘Prospects for personalised medicine using advanced biological therapies’’ (2021) Open Access Government
MORRISON M, ‘Biomodifying technologies Policy Briefing 2 “Accelerating innovation: speed and timing in translational research”’ (2020) RegMedNet
MORRISON M, ‘Biomodifying technologies Policy Briefing 1 “Making good targets for translational research”’ (2020) RegMedNet
Morrison M, ‘Targeted policy support for emerging biomedical innovations’’ (2020) Open Access Government
Morrison M, ‘Research using free text data in medical records could benefit from dynamic consent and other tools for responsible governance’ (2020) Journal of Medical Ethics 367
Feeney O and others, ‘Response to Open Peer Commentaries on "Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies".’ (2019) W10
MORRISON M, ‘Book Review: Petersen, A., Munsie, M., Tanner, C., MacGregor, C. and Brophy, J.Stem Cell Tourism and the Political Economy of Hope. London: Palgrave Macmillan. 2017’ (2018) Wiley 1434
Morrison M, Bell J and Isasi R, ‘Chapter 2: stem cell use’ (2018) Genotoul Societal
Morrison M, Dickenson D and Lee S, ‘Introduction to the article collection ’Translation in healthcare: ethical, legal, and social implications’.’ (2016) 74
Morrison M, ‘Report from the MHRA Patient Forum on Biomodifying Technologies January 2020’ (Zenodo 2021)
Bell J and others, ‘Governing stem cells: regenerative medicine in Europe - the vision and recommendations from the EUCelLEX project’ (Genotoul Societal 2018)
A Martin P and Morrison M, ‘Realising the potential of genomic medicine’ (Royal Pharmaceutical Society of Great Britain; London 2006)